Yanpothung Yanthan

Yanpothung Yanthan

Auto-generated profile, based on publicly available information

Yanpothung Yanthan

Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Brain Tumor Research and Treatment
Verified
Journal Article
Open access
PDF file
PSPrashasti Sharma
Prashasti Sharma
PMPartha Pratim Medhi
Partha Pratim Medhi
AKApurba Kumar Kalita
Apurba Kumar Kalita
MBMouchumee Bhattacharyya
Mouchumee Bhattacharyya
JNJyotiman Nath
Jyotiman Nath
YYYanpothung Yanthan
Yanpothung Yanthan
Sharma P, et al. Brain Tumor Res Treat. 2023 Jul;11(3):183-190. https://doi.org/10.14791/btrt.2023.0004

4 November 2023 in Cureus
Verified
Journal Article
Open access
PDF file
JDJahnabi Das
Jahnabi Das
SMShantanu K. Mishra
Shantanu K. Mishra
MSMoirangthem N. Singh
Moirangthem N. Singh
MBMouchumee Bhattacharyya
Mouchumee Bhattacharyya
YYYanpothung Yanthan
Yanpothung Yanthan
AKApurba K. Kalita
Apurba K. Kalita
Purpose This study compares the dosimetry and dose sparing of cardiac substructures in single isocenter and dual isocenter RapidArc™ (Varian Medical Systems, Palo Alto, California, United States) radiotherapy planning for synchronous bilateral breast cancer. Methodology Six synchronous bilateral breast cancer (SBBC) patients received adjuvant radiation with the prescribed dose of 40.05 Gy in 15 fractions to the planning target volume (PTV) without local lymph nodal regions. PTVs and organs at risk (OARs), including both lungs, esophagus, spinal cord, heart, and left anterior descending coronary artery (LAD), both atria and ventricles were contoured. Single isocentric RapidArc (SIRA) and dual isocentric RapidArc (DIRA) plans were made for each patient and dosimetric differences between these two techniques were evaluated. Results There was no statistically significant difference in conformity index (CI) values between SIRA and DIRA plans, with 0.9681±0.01 and 0.9721±0.01 (p=0.505), respectively. SIRA planning showed superior homogeneity with homogeneity Index (HI) values of 0.0999±0.01 compared to DIRA planning with HI values of 0.1640±0.12 (p=0.230). The mean LAD dose of SIRA was valued higher than that of DIRA planning. Lower mean doses were obtained for both lungs in SIRA plans compared to DIRA plans. Meanwhile, doses to the right atrium, left atrium, left ventricle, right ventricle, and esophagus showed no statistical significance between these two techniques, except in the spinal cord. Conclusion Both SIRA and DIRA plans have satisfactory outcomes in sparing OARs. Meanwhile, SIRA techniques have less setup time and overall machine time.

25 August 2020 in International Journal of Otorhinolaryngology and Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
SPShreeya Pabi
Shreeya Pabi
YYYanpothung Yanthan
Yanpothung Yanthan
SGSweety Gupta
Sweety Gupta
BDBiswajyoti Das
Biswajyoti Das
AIAjas Ibrahim
Ajas Ibrahim
MGManoj Gupta
Manoj Gupta
We are reporting an uncommon case of second primary chondrosarcoma of the maxilla in a 52-year-old male patient. Patient had first been diagnosed in 2004 with chondrosarcoma of the right maxilla. He had undergone right partial maxillectomy for the same. Since 2016 he had started noticing a swelling over the left side of the maxilla. Repeated biopsies from the growth showed no evidence of any malignancy. Hence, he was kept on routine follow up. However, in 2018, during follow up the growth had increased in size - hard swelling present in remnant post partial maxillectomy cavity, non-tender -and a punch biopsy was taken, revealing a well differentiated chondrosarcoma. A diagnosis of second primary chondrosarcoma of the maxilla was made based on Warren and Gates criteria. A brief discussion on the radiologic and histologic presentation of the tumor and the treatment modalities of this unusual tumor is discussed.

21 October 2023 in Asian Pacific Journal of Cancer Care
Verified
Journal Article
Open access
PDF file
ADAbhinandan Das
Abhinandan Das
AKApurba Kumar Kalita
Apurba Kumar Kalita
MBMouchumee Bhattacharyya
Mouchumee Bhattacharyya
JNJyotiman Nath
Jyotiman Nath
YYYanpothung Yanthan
Yanpothung Yanthan
MSMongal Sonar
Mongal Sonar
Background: Esophageal cancer is a highly aggressive malignancy often associated with a poor prognosis because of locoregional failure and distant metastases. About 60–70 percent of the patients present at an advanced stage, have a median survival in the range of 6-10 months, and are not amenable to definitive treatment. Dysphagia is the most common complaint, seen in 80%–90% of patients. The priority for managing patients with advanced disease is dysphagia control, which in turn can improve nutritional intake and quality of life. External-beam radiotherapy (EBRT) is one of the major means of palliation. Objective: The primary goal of our study was to assess the efficacy of external beam radiotherapy in alleviating dysphagia in patients with esophageal cancer.Materials and method: This was a single arm prospective clinical study conducted in a tertiary care hospital in northeast India. The study comprised of 57 esophageal cancer patients, ineligible for definitive treatment. The patients received EBRT of 30 Gy in 10 fractions over two weeks. Dysphagia was graded using Modified Takita’s grading system. Patients were followed up at one-month intervals after treatment to assess dysphagia and acute toxicity. Results: Out of 57 patients in the study, subjective dysphagia relief was seen in 82.45%. The median dysphagia score decreased from 3 to 2 at the end of the 3-month post treatment period. (p < .001). In terms of treatment-related toxicity, treatment was well tolerated. No grade 4-5 toxicity was encountered. The most commonly encountered toxicity was radiation esophagitis, which affected 15 patients (26.31%).Conclusion: Radiation significantly improves dysphagia in esophageal cancer patients. It is an effective, non-invasive, and well-tolerated way to treat dysphagia in selected individuals with incurable esophageal cancer.


1 August 2023 in JCO Global Oncology
Verified
Journal Article
Closed access
PSPrashasti Sharma
Prashasti Sharma
MBMouchumee Bhattacharyya
Mouchumee Bhattacharyya
PMPartha Pratim Medhi
Partha Pratim Medhi
JNJyotiman Nath
Jyotiman Nath
PRPartha Roy
Partha Roy
TDTapashi Das
Tapashi Das